Skip to main content

08-16-2018 | Pregnancy | Review | Article

Glucose Targets and Insulin Choice in Pregnancy: What Has Changed in the Last Decade?

Current Diabetes Reports

Authors: Siobhán Bacon, Denice S. Feig

Publisher: Springer US


Purpose of Review

To review current glycaemic targets and the potential use of newer insulin formulations in pregnancy.

Recent Findings

The impact of stricter glycaemic control on perinatal outcomes remains controversial, showing conflicting results. Current ongoing randomised trials investigating the role of tighter glucose targets in pregnancy should help clarify the benefit of tighter glucose control. Optimal timing for self-monitoring blood glucose (SMBG) remains debatable. Data suggest that post-prandial SMBG, particularly at 1 h, offers the best prediction of adverse perinatal outcome. To achieve these targets, insulin is the standard therapy. Novel insulin formulations offer benefits outside of pregnancy. Recent data on the use of new insulins in pregnancy (e.g. insulin degludec and glargine (U 300)) is limited to case reports.


Glycaemic targets have remained unchanged in the last decade. Studies using stricter glycaemic targets may improve perinatal outcomes. Newer insulin formulations may offer increased flexibility and glycaemic control. Clinicians caring for women with diabetes striving to minimise adverse perinatal outcomes will find this review of interest.

Please log in to get access to this content

Related topics

Flash glucose monitoring technology

Browse new slide sets summarizing the latest results from real-world studies.

Image Credits